OUR STORY

News and Reports

Ludwig scientists around the world are continually making discoveries that alter our understanding of cancer. Our science is featured in the most prestigious journals and in general media. Explore some of our most recent findings, news and reports.

For media inquiries, contact
Rachel Steinhardt
​Vice President of Communications

T 1 212 450 1582

Ludwig in the news

2017

Apr 01, 2017

The Scientist
Ludwig Oxford scientist Colin Goding’s recent Genes & Development study was selected as the Editor’s Choice in Cancer Biology for The Scientist’s April issue. As previously reported, the study identified an ancient, cellular starvation response, conserved through eons of evolution, that underlies the spread of the aggressive skin cancer melanoma. 

Mar 25, 2017

Oncology Times
Ludwig Oxford scientist Colin Goding examines why cancer cells spread within the body and explains how understanding this process can help devise new treatment options. 

Feb 10, 2017

The San Diego Union-Tribune
The San Diego Union-Tribune covers Paul Mischel's latest research in this article, which includes a video of Mischel's lab. In the video, Mischel describes how his team recently found that oncogenes “jump off” chromosomes onto extrachromosomal circles of DNA, driving tumor evolution and drug resistance. If we better understood the mechanisms behind this activity, Mischel says, we might be able to develop more effective cancer treatments.

Feb 08, 2017

Nature Podcast
In this podcast, Paul Mischel fields questions about the recent study he led that upends old assumptions about cancer genes. Mischel's findings will shift how cancer diversity and resistance are understood and studied.

Feb 08, 2017

The Scientist
A recent study led by Ludwig San Diego's Paul Mischel is likely to change the way tumor evolution is understood by scientists and could ultimately lead to new ways to prevent and treat many malignancies. The Scientist reports on the findings and includes perspectives from several scientists not involved in the study.

2016

Nov 10, 2016

GEN
Researchers led by Ludwig MSK's Taha Merghoub reported how a targeted drug can reverse the effects of certain immune cells that suppress responses to cancer immunotherapy. ​"We can now potentially identify patients whose tumors possess immune suppressor cells and add a drug to their treatment regimen to specifically disarm them," Merghoub tells GEN.

2014

Feb 10, 2014

Chicago PBS 'WTTW TV'